Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Monitoring for lack of benefit: a critical component of a randomized clinical trial.

Freidlin B, Korn EL.

J Clin Oncol. 2009 Feb 1;27(4):629-33. doi: 10.1200/JCO.2008.17.8905. Epub 2008 Dec 8.

2.

Data monitoring committees and interim monitoring guidelines.

Freidlin B, Korn EL, George SL.

Control Clin Trials. 1999 Oct;20(5):395-407. Review.

PMID:
10503800
3.

Issues in data monitoring and interim analysis of trials.

Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA; DAMOCLES study group.

Health Technol Assess. 2005 Mar;9(7):1-238, iii-iv. Review.

4.

Futility approaches to interim monitoring by data monitoring committees.

Demets DL.

Clin Trials. 2006;3(6):522-9. Review.

PMID:
17170036
5.

Generalizing results of randomized trials to clinical practice: reliability and cautions.

Flather M, Delahunty N, Collinson J.

Clin Trials. 2006;3(6):508-12. Review.

PMID:
17170034
6.
7.

Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect".

Braunholtz DA, Edwards SJ, Lilford RJ.

J Clin Epidemiol. 2001 Mar;54(3):217-24. Review.

PMID:
11223318
8.
9.

[The limits of controlled clinical studies: the case of rheumatology].

Portioli I.

Ann Ital Med Int. 2000 Jan-Mar;15(1):39-46. Review. Italian.

PMID:
10842890
10.

Randomized controlled trials of home uterine activity monitoring: a review and critique.

Grimes DA, Schulz KF.

Obstet Gynecol. 1992 Jan;79(1):137-42. Review.

PMID:
1727572
11.

Non-inferiority trials in surgical oncology.

Fueglistaler P, Adamina M, Guller U.

Ann Surg Oncol. 2007 May;14(5):1532-9. Epub 2007 Feb 9. Review.

PMID:
17294075
12.

Cost-effectiveness as an outcome in randomized clinical trials.

Hlatky MA, Owens DK, Sanders GD.

Clin Trials. 2006;3(6):543-51. Review.

PMID:
17170039
13.

Clinical trial design in systemic lupus erythematosus.

Dall'Era M, Wofsy D.

Curr Opin Rheumatol. 2006 Sep;18(5):476-80. Review.

PMID:
16896285
14.

Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J.

Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. Review.

15.
16.

A group sequential, response-adaptive design for randomized clinical trials.

Karrison TG, Huo D, Chappell R.

Control Clin Trials. 2003 Oct;24(5):506-22. Review.

PMID:
14500050
17.

A clinical development paradigm for cancer vaccines and related biologics.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group.

J Immunother. 2007 Jan;30(1):1-15. Review.

PMID:
17198079
18.

The role of external evidence in data monitoring of a clinical trial.

Pocock SJ.

Stat Med. 1996 Jun 30;15(12):1285-93; discussion 1295-7. Review.

PMID:
8817802
19.

Clinical hypertension research tools: the randomized controlled clinical trial.

Lackland DT, Woolson RF.

J Clin Hypertens (Greenwich). 2006 Jun;8(6):427-31; quiz 432-3. Review.

20.

Methods and design considerations for randomized clinical trials evaluating surgical or endovascular treatments for cerebrovascular diseases.

Qureshi AI, Hutson AD, Harbaugh RE, Stieg PE, Hopkins LN; North American Trial of Unruptured and Ruptured Aneurysms Planning Committee.

Neurosurgery. 2004 Feb;54(2):248-64; discussion 264-7. Review.

PMID:
14744272

Supplemental Content

Support Center